First patient dosed with Sosei's oral immunotherapy drug

The first patient has been dosed with an orally available small molecule cancer immunotherapy drug, Sosei Group Corporation and Cancer Research UK have announced.

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,London ,City Of ,Sosei Heptare ,Bristi Basu ,Nigel Blackburn ,Sosei Heptares ,Matt Barnes ,Debashis Sarker ,United Kingdom At Cambridge University Hospitals ,Regulatory Agency ,Experimental Cancer Medicine Centre ,King College London ,University Of Cambridge ,Sosei Group Corporation ,Cancer Research United Kingdom ,Group Corporation ,Heptares Therapeutics ,Research United Kingdom ,Drug Development ,College London ,Cambridge University Hospitals ,United Kingdom Medicines ,Innovation Passport ,Licensing Access Pathway ,Innovation Passports ,Clinical Development ,Markets Amp Regulations ,Pis Active Pharmaceutical Ingredients ,Hasei Ii ,Immunotherapy ,Immuno Oncology ,Ncology ,Clinical Trials ,Dancer ,